BioSpace News Archive

Replimune Group, Inc. announced initial data from ARTACUS, a Phase 1/2 trial evaluating RP1 for the treatment of cutaneous malignancies in patients who have had a kidney, liver, heart, lung, and/or a hematopoietic cell transplant.

UroMems, a global company developing innovative, mechatronics technology to treat stress urinary incontinence (SUI), announced today that it has successfully met the primary endpoints for the initial male patient in its SOPHIA study.

Brand Institute is proud to announce its work with Lexicon Pharmaceuticals, Inc. in developing the brand name INPEFA™ (sotagliflozin), which was approved by the FDA on May 26, 2023.

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with William Pao, Chief Development Officer, Executive Vice President, at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13, 2023 at 8:00 a.m. Pacific Daylight Time.

SYNAPS Dx a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease, recognizes June 2023 Alzheimer’s & Brain Awareness Month as an opportunity to raise awareness about brain disorders, including AD and other dementias, and the need for more accurate diagnostic tools.

Olympus Corporation, a global medical technology company committed to making people’s lives healthier, safer and more fulfilling, announced market availability of its newest electrosurgical generator for use in the treatment of bladder cancer and enlarged prostate.

Today, the U.S. Food and Drug Administration is announcing the availability of a draft guidance with updated recommendations for good clinical practices (GCPs) aimed at modernizing the design and conduct of clinical trials, making them more agile without compromising data integrity or participant protections.

From June 5th to 8th (Pacific Standard Time), the 2023 BIO International Convention (“BIO 2023") will be held in Boston, Massachusetts , USA.

icometrix , world leader in imaging artificial intelligence (AI) solutions for people with neurological conditions, has been awarded a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to continue efforts in research towards brain MRI biomarkers for Parkinson’s disease (PD).

Kite, a Gilead Company (Nasdaq: GILD), today announces findings from the largest real-world analysis to date of Tecartus® (brexucabtagene autoleucel) in patients with relapsed or refractory mantle cell lymphoma (R/R MCL).